Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Black cohosh

This article was originally published in The Tan Sheet

Executive Summary

Australia's Therapeutic Goods Association is requiring a warning on all products containing black cohosh that reads, "Warning: Black cohosh may harm the liver in some individuals. Use under the supervision of a healthcare professional," the country's government announces Feb. 9. TGA reviewed the safety of black cohosh to find 47 cases of liver reactions worldwide, including nine cases in Australia. "Considering the widespread use of black cohosh, the incidence of liver reaction appears to be very low," TGA states. However, four of the nine Australians who suffered liver problems were hospitalized and two required transplants. New products must comply with the requirement from the time of their launch, but existing products have a 12-month phase-in period...

You may also be interested in...



EU Agencies Call Attention To Link Between Black Cohosh, Liver Risks

The UK's Medicines & Healthcare products Regulatory Agency (MHRA) will add warnings to black cohosh products about the risk of liver disorders associated with use of the herbal, the agency states in a release July 18

Reimbursement Questions Jeopardize Hillrom/Bardy Merger

Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.

Boston Scientific Pays More Than $1Bn For Lumenis’ Surgical Laser Business

Lumenis’ surgical business includes the MOSES laser system for minimally invasive urology surgery which will complement Boston Scientific’s LithoVue ureteroscope.

Topics

UsernamePublicRestriction

Register

LL005491

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel